Similar findings were observed in the present study, which showed that concurrent TRT and anti-PD-L1 mAb (administered on days 1, 4, and 7 after TRT) conferred significantly enhanced anti-tumor efficacy and longer overall survival than sequential therapy. Here, CD274 is linked to neoplasm.